NasdaqGM - Nasdaq Real Time Price USD

Supernus Pharmaceuticals, Inc. (SUPN)

Compare
30.75 -0.02 (-0.06%)
At close: September 27 at 4:00 PM EDT
30.75 0.00 (0.00%)
After hours: September 27 at 5:24 PM EDT
Loading Chart for SUPN
DELL
  • Previous Close 30.77
  • Open 30.85
  • Bid 30.70 x 100
  • Ask 30.80 x 100
  • Day's Range 30.63 - 31.40
  • 52 Week Range 21.99 - 35.44
  • Volume 294,058
  • Avg. Volume 440,606
  • Market Cap (intraday) 1.694B
  • Beta (5Y Monthly) 0.89
  • PE Ratio (TTM) 341.67
  • EPS (TTM) 0.09
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 39.25

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

www.supernus.com

652

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SUPN

View More

Performance Overview: SUPN

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SUPN
6.25%
S&P 500
20.30%

1-Year Return

SUPN
5.27%
S&P 500
34.27%

3-Year Return

SUPN
10.57%
S&P 500
28.79%

5-Year Return

SUPN
11.78%
S&P 500
92.71%

Compare To: SUPN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SUPN

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    1.69B

  • Enterprise Value

    1.39B

  • Trailing P/E

    341.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.67

  • Price/Book (mrq)

    1.77

  • Enterprise Value/Revenue

    2.20

  • Enterprise Value/EBITDA

    11.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.83%

  • Return on Assets (ttm)

    1.95%

  • Return on Equity (ttm)

    0.56%

  • Revenue (ttm)

    630.16M

  • Net Income Avi to Common (ttm)

    5.24M

  • Diluted EPS (ttm)

    0.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    347.19M

  • Total Debt/Equity (mrq)

    4.18%

  • Levered Free Cash Flow (ttm)

    219.26M

Research Analysis: SUPN

View More

Company Insights: SUPN

Research Reports: SUPN

View More

People Also Watch